These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12841068)

  • 1. Total, free and complexed PSA and hK2 for early detection of prostate cancer.
    Haese A; Khan MA; Sokoll LJ
    MLO Med Lab Obs; 2003 Jun; 35(6):14-6, 20, 22 passim; quiz 30-1. PubMed ID: 12841068
    [No Abstract]   [Full Text] [Related]  

  • 2. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free and total human glandular kallikrein 2 in patients with prostate cancer.
    Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
    Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
    Zlotta A; Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A201-5. PubMed ID: 10523893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
    Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
    Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
    Väisänen V; Peltola MT; Lilja H; Nurmi M; Pettersson K
    Anal Chem; 2006 Nov; 78(22):7809-15. PubMed ID: 17105175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are multiple markers the future of prostate cancer diagnostics?
    Mikolajczyk SD; Song Y; Wong JR; Matson RS; Rittenhouse HG
    Clin Biochem; 2004 Jul; 37(7):519-28. PubMed ID: 15234233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hK2 in predicting clinically insignificant prostate cancer.
    Briganti A
    Eur Urol; 2007 Nov; 52(5):1297-9. PubMed ID: 17822837
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.
    Lilja H; Stenman UH
    Cancer Treat Res; 1996; 88():93-101. PubMed ID: 9239474
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
    J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
    Tajiri M; Ohyama C; Wada Y
    Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen: an updated review.
    So A; Goldenberg L; Gleave ME
    Can J Urol; 2003 Dec; 10(6):2040-50. PubMed ID: 14704108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
    Bangma CH; Wildhagen MF; Yurdakul G; Schröder FH; Blijenberg BG
    BJU Int; 2004 Apr; 93(6):720-4. PubMed ID: 15049979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.